

Study Shows Epigenetic Changes in Children with Crohn's Disease

A Host of New Clues on Gene-Environment Interactions in Crohn's Disease, Reports Inflammatory Bowel Disease

August 22, 2014 - A new study finds a wide range of epigenetic changes—alterations in DNA across the genome that may be related to key environmental exposures—in children with Crohn's disease (CD), reports [Inflammatory Bowel Diseases](#), official journal of the [Crohn's & Colitis Foundation of America](#) (CCFA). The journal is published by [Lippincott Williams & Wilkins](#), a part of [Wolters Kluwer Health](#).

The study provides "compelling evidence" of alterations of DNA in several regions of the genome in children with CD, according to Professor Jack Satsangi of University of Edinburgh and colleagues. In addition to providing new insights into how genes and the environment interact, the results may have early implications for clinical management of CD.

Epigenetic Changes in Childhood-Onset Crohn's Disease

The researchers performed a "genome-wide" study in children with newly diagnosed CD, before any treatment, to look for possible epigenetic changes that may affect gene behavior. Epigenetic changes reflect the impact of a wide range of environmental factors on genes.

The results showed strong evidence of such changes at 65 different sites across the genome. Nineteen sites showed clustering of epigenetic changes, pointing at genetic pathways that might be relevant to CD development.

Similar patterns were present in a separate group of children who had been treated for CD, as well as in a group of treated adults.

The study highlighted "highly significant" changes in two specific gene locations (loci), which include genes responsible for immune and cellular functions that could contribute to the development of CD. Two probes for these loci were highly accurate in predicting which children would have CD, providing a potentially useful "biomarker" for use as a diagnostic test.

'Exciting and Immediate Implications' for Clinical Management

One specific gene location seemed particularly important, as it has been implicated in a number of different cancers, including colorectal cancer. The same area has a known role in the development of T-cells, a key type of immune cell.

The study also identified a number of other loci that might play a role in the development of CD, warranting further study.

The new research adds to the growing body of evidence of epigenetic changes in diseases such as rheumatoid arthritis, multiple sclerosis, type 2 diabetes, and obesity. The findings highlight the importance of combining information on DNA changes, genes, and gene expression in future studies of these and other complex diseases, Dr Satsangi and colleagues believe.

Crohn's disease is a painful, medically incurable illness that may attack anywhere along the digestive system. Crohn's disease and ulcerative colitis, which involves only the large intestine (colon), are the



two main types of inflammatory bowel disease. Some 1.4 million American adults and children suffer from CD or ulcerative colitis.

Although much more research is needed to understand the epigenetic changes, the investigators believe their findings could lead to advances in clinical management of childhood-onset CD in the near future. They write, "There are exciting and immediate implications for early clinical translation; the discovery of easily accessible biomarkers in peripheral blood to predict disease susceptibility, progression or response to therapy and the potential for new therapeutic targets."

[Click here to read "Two-stage Genome-wide Methylation Profiling in Childhood-onset Crohn's Disease Implicates Epigenetic Alterations at the VMP1/MIR21 and HLA Loci."](#)

Note to editors: For further information, contact Erin Stoeber, Vice President of Marketing & Communications for the CCFA: phone 646-327-3746 or e-mail estoeber@ccfa.org.

About Inflammatory Bowel Diseases

[Inflammatory Bowel Diseases](#) brings the most current information in clinical and basic sciences to physicians caring for patients with inflammatory bowel diseases, and investigators performing research in IBD and related fields. Each issue contains cutting-edge original basic science and clinical articles on diagnosis, treatment, and management of IBD from clinicians and researchers around the world. Coverage includes articles highlighting the unique and important issues in pediatric IBD, as well as articles pertaining to adult patients.

About CCFA

The [Crohn's & Colitis Foundation of America](#) (CCFA) is the largest voluntary non-profit health organization dedicated to finding cures for Inflammatory Bowel Diseases (IBD). CCFA's mission is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults who suffer from these diseases. The Foundation works to fulfill its mission by funding research, providing educational resources for patients and their families, medical professionals, and the public, and furnishing supportive services for those afflicted with IBD. For more information, visit www.ccfa.org, call 888-694-8872, like us on Facebook, or follow us on Twitter.

About Wolters Kluwer Health

[Wolters Kluwer Health](#) is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries worldwide, clinicians rely on Wolters Kluwer Health's market leading information-enabled tools and software solutions throughout their professional careers from training to research to practice. Major brands include [Health Language](#)[®], [Lexicomp](#)[®], [Lippincott Williams & Wilkins](#), [Medicom](#)[®], [Medi-Span](#)[®], [Medknow](#), [Ovid](#)[®], [Pharmacy OneSource](#)[®], [ProVation](#)[®] [Medical](#) and [UpToDate](#)[®].

Wolters Kluwer Health is part of [Wolters Kluwer](#), a market-leading global information services company. Wolters Kluwer had 2013 annual revenues of €3.6 billion (\$4.7 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

Follow our official Twitter handle: [@WKHealth](https://twitter.com/WKHealth).

Media Contact:

Robert Dekker
Vice President, Communications
Wolters Kluwer Health

Connie Hughes
Director, Corporate Communications
Wolters Kluwer, Medical Research



Wolters Kluwer

+1 (215) 521-8928

Robert.Dekker@wolterskluwer.com

+1 (646) 674-6348

Connie.Hughes@wolterskluwer.com